Market Overview:
The global COPD and asthma devices market is expected to grow at a CAGR of 5.8% from 2018 to 2030. The growth in the market can be attributed to the increasing prevalence of COPD and asthma, rising awareness about these diseases, and technological advancements in the field of respiratory devices. The global COPD and asthma devices market is segmented by type into metered dose inhalers (MDI), drug powder inhalers (DPI), soft mist inhalers, jet nebulizers, ultrasonic nebulizers, and others. The MDI segment is expected to dominate the market during the forecast period owing to its high usage rates across all regions. However, DPI is projected to grow at a higher CAGR during the forecast period as it offers several advantages over MDIs such as reduced medication wastage, improved patient compliance due to smaller particle size delivery of drugs resulting in better lung deposition with less side effects as compared with MDIs. On basis of application, hospitals are estimated ot account for majority share of revenue generated by this market during 2018-2030 owing large number if patients suffering from chronic respiratory diseases seeking treatment in hospitals setting globally .
Product Definition:
COPD and asthma devices are important for people who suffer from these respiratory conditions. They help to improve air flow and breathing, making it easier for people with COPD or asthma to breathe.
Metered Dose Inhalers (MDI):
Metered dose inhalers (MDI) are a type of asthma inhaler that contains medication and is used to treat an acute asthma attack. MDIs work by delivering precise doses of bronchodilators through the mouth and into the lungs, where they are absorbed more quickly than from a sputum. The metered dose inhalers were first approved in the U.S in 1983 under the brand name Proventil; it is currently manufactured by Teva Pharmaceuticals Ltd.
Drug Powder Inhalers (DPI):
Drug powder inhalers (DPI) are a type of asthma medication that is used to treat symptoms of COPD and allergies associated with bronchial tubes. The drug works by causing the smooth muscle in the lungs to relax, which allows air to pass more easily through the lung tissue.
The global DPI market was valued at USD 1.8 billion in 2013.
Application Insights:
Based on the application, the global COPD and asthma devices market is segmented into hospitals, clinics, and others. The hospitals segment dominated the overall market in terms of revenue in 2017. This high share can be attributed to factors such as a large patient base with diagnosed COPD and/or asthma across various hospitals globally. Furthermore, an increase in hospital-based clinical trials for new drugs for treatment of COPD and asthma will boost product demand over the forecast period.
The clinics segment is expected to witness significant growth during the forecast period owing to increasing awareness about treatments related to COPD among patients suffering from bronchitis or cough throughout various walk-in clinics or pharmacies that offer limited diagnostic services due to financial constraints. Such initiatives by public health authorities will also contribute toward industry growth during this study period.
Regional Analysis:
North America dominated the global COPD and asthma devices market in 2017. This can be attributed to increasing awareness about asthma, favorable government initiatives, and availability of highly skilled physicians & healthcare professionals. Moreover, high adoption of these devices due to technological advancements is also expected to drive the regional market over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to factors such as rising geriatric population prone towards various respiratory diseases along with increasing disposable income & consumer awareness regarding available treatment options for COPD. In addition, a large number of patients suffering from other chronic conditions are also driving this region’s growth rate significantly.
Key countries analyzed in this study include China; India; Japan; Australia; South Korea; Indonesia.; Malaysia.; Philippines.; Thailand.; Vietnam., Saudi Arabia., UAE.
Growth Factors:
- Increasing prevalence of COPD and asthma
- Rising awareness about the benefits of using COPD and asthma devices
- Technological advancements in COPD and asthma devices
- Growing demand for home-based respiratory care therapies
- Increasing number of product approvals by regulatory authorities
Scope Of The Report
Report Attributes
Report Details
Report Title
COPD and Asthma Devices Market Research Report
By Type
Metered Dose Inhalers (MDI), Drug Powder Inhalers (DPI), Soft Mist Inhalers, Jet Nebulizers, Ultrasonic Nebulizers, Others
By Application
Hospitals, Clinics, Others
By Companies
GlaxoSmithKline Plc, Novartis AG, Merck & Co., Inc, AstraZeneca Plc, Philips Healthcare, M Health Care, Allied Healthcare Products Inc, Sunovion Pharmaceuticals Inc, GF Healthcare Products, Smith Medicals, GlaxoSmithKline Plc, Baxter International
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
161
Number of Tables & Figures
113
Customization Available
Yes, the report can be customized as per your need.
Global COPD and Asthma Devices Market Report Segments:
The global COPD and Asthma Devices market is segmented on the basis of:
Types
Metered Dose Inhalers (MDI), Drug Powder Inhalers (DPI), Soft Mist Inhalers, Jet Nebulizers, Ultrasonic Nebulizers, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- GlaxoSmithKline Plc
- Novartis AG
- Merck & Co., Inc
- AstraZeneca Plc
- Philips Healthcare
- M Health Care
- Allied Healthcare Products Inc
- Sunovion Pharmaceuticals Inc
- GF Healthcare Products
- Smith Medicals
- GlaxoSmithKline Plc
- Baxter International
Highlights of The COPD and Asthma Devices Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Metered Dose Inhalers (MDI)
- Drug Powder Inhalers (DPI)
- Soft Mist Inhalers
- Jet Nebulizers
- Ultrasonic Nebulizers
- Others
- By Application:
- Hospitals
- Clinics
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the COPD and Asthma Devices Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
COPD is a chronic lung disease that includes symptoms such as coughing, shortness of breath, and wheezing. Asthma devices are used to control asthma symptoms.
Some of the major companies in the copd and asthma devices market are GlaxoSmithKline Plc, Novartis AG, Merck & Co., Inc, AstraZeneca Plc, Philips Healthcare, M Health Care, Allied Healthcare Products Inc, Sunovion Pharmaceuticals Inc, GF Healthcare Products, Smith Medicals, GlaxoSmithKline Plc, Baxter International.
The copd and asthma devices market is expected to register a CAGR of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 COPD and Asthma Devices Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 COPD and Asthma Devices Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 COPD and Asthma Devices Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the COPD and Asthma Devices Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global COPD and Asthma Devices Market Size & Forecast, 2020-2028
4.5.1 COPD and Asthma Devices Market Size and Y-o-Y Growth
4.5.2 COPD and Asthma Devices Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Metered Dose Inhalers (MDI)
5.2.2 Drug Powder Inhalers (DPI)
5.2.3 Soft Mist Inhalers
5.2.4 Jet Nebulizers
5.2.5 Ultrasonic Nebulizers
5.2.6 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global COPD and Asthma Devices Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 COPD and Asthma Devices Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Metered Dose Inhalers (MDI)
9.6.2 Drug Powder Inhalers (DPI)
9.6.3 Soft Mist Inhalers
9.6.4 Jet Nebulizers
9.6.5 Ultrasonic Nebulizers
9.6.6 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Metered Dose Inhalers (MDI)
10.6.2 Drug Powder Inhalers (DPI)
10.6.3 Soft Mist Inhalers
10.6.4 Jet Nebulizers
10.6.5 Ultrasonic Nebulizers
10.6.6 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Metered Dose Inhalers (MDI)
11.6.2 Drug Powder Inhalers (DPI)
11.6.3 Soft Mist Inhalers
11.6.4 Jet Nebulizers
11.6.5 Ultrasonic Nebulizers
11.6.6 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Metered Dose Inhalers (MDI)
12.6.2 Drug Powder Inhalers (DPI)
12.6.3 Soft Mist Inhalers
12.6.4 Jet Nebulizers
12.6.5 Ultrasonic Nebulizers
12.6.6 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Metered Dose Inhalers (MDI)
13.6.2 Drug Powder Inhalers (DPI)
13.6.3 Soft Mist Inhalers
13.6.4 Jet Nebulizers
13.6.5 Ultrasonic Nebulizers
13.6.6 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 COPD and Asthma Devices Market: Competitive Dashboard
14.2 Global COPD and Asthma Devices Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 GlaxoSmithKline Plc
14.3.2 Novartis AG
14.3.3 Merck & Co., Inc
14.3.4 AstraZeneca Plc
14.3.5 Philips Healthcare
14.3.6 M Health Care
14.3.7 Allied Healthcare Products Inc
14.3.8 Sunovion Pharmaceuticals Inc
14.3.9 GF Healthcare Products
14.3.10 Smith Medicals
14.3.11 GlaxoSmithKline Plc
14.3.12 Baxter International
